Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patients

The Partial 5-Hydroxytryptamine1A Receptor Agonist Buspirone does not Antagonize Morphine-induced Respiratory Depression in Humans

“…After a baseline session consisting of assessments of respiratory depression and pain (session 1), the participants swallowed two opaque gelatin capsules (for blinding) containing either 60 mg buspirone hydrochloride or placebo, together with 100 ml lukewarm tap water. The dose of 60 mg was chosen because it was the upper limit of safe buspirone dosing to healthy volunteers found in the literature 50 , 51 . In terms of clinical dosing, 60 mg are twice the recommended daily dose.…”

Evidence for a Re-Evaluation of the Neurochemical and Anatomical Bases of Chemotherapy-Induced Vomiting

“…Unlike the proemetic 5-HT 3/4 receptors, stimulation of 5-HT 1A receptors by different full and partial agonists seems to exert antiemetic activity in diverse species against several emetic stimuli including: motion, nicotine, cisplatin, CuSO 4 , veratrine, cisplatin, mechanical stimulation of the upper gastrointestinal tract in the house musk shrew; , motion, cisplatin, or xylazine in the cat; − ipecac, emetine, mCPBG, cisplatin, or cyclophosphamide in pigeons; , and cisplatin . However, in the clinical setting, 5-HT 1A agonists are found not to be an effective antiemetic in cancer patients receiving chemotherapy . They also cause side effects such as nausea and vomiting in patients when taken as medication for conditions such as depression. − Species differences and dopaminergic agonism of some compounds have already been suggested as possible explanations for the opposing basic and clinical findings .…”

“…192 However, in the clinical setting, 5-HT 1A agonists are found not to be an effective antiemetic in cancer patients receiving chemotherapy. 193 They also cause side effects such as nausea and vomiting in patients when taken as medication for conditions such as depression. [194][195][196][197] Species differences and dopaminergic agonism of some compounds have already been suggested as possible explanations for the opposing basic and clinical findings.…”

Randomized, Multicenter Comparison of Oral Granisetron and Oral Ondansetron for Emetogenic Chemotherapy

“…The trial evaluated a single intravenous dose of ondansetron 8 mg, a single oral dose of ondansetron 16 mg, or two doses of buspirone 60 mg in patients receiving cisplatin. 10 Five of nine patients receiving oral ondansetron and six of nine receiving intravenous ondansetron had no emesis, whereas all patients receiving buspirone experienced emesis. Since the bioavailability of oral ondansetron is approximately 50%, the authors doubled the standard intravenous dose of 8 mg and administered it as a single 16-mg oral dose.…”